Submitted FDA De Novo application for ARC-EX® System
Successfully raised
Announced positive top-line results from Up-LIFT pivotal study
Forged partnership to provide rapid access to
Continued to pioneer brain-computer interface therapies for SCI
EINDHOVEN,
“In 2023, we made substantial progress against our objectives and laid the foundation to bring our ARC-EX System to the US market later this year,” said
Full Year 2023 and Early 2024 Highlights
Clinical and Development:
- In
April 2023 at theAmerican Academy of Neurology Annual Meeting, neurosurgeon Dr.James Guest of theUniversity of Miami and theMiami Project to Cure Paralysis shared that in addition to meeting all primary safety and effectiveness endpoints, the Up-LIFT pivotal study demonstrated that 72% of participants responded to ARC-EX Therapy1. - In
May 2023 , Nature published on the progress of a participant from a 2021 clinical feasibility study in which the Company’s ARC-IM® Therapy was paired with an implanted brain-computer interface (BCI) for the first time, resulting in that individual gaining augmented control over when and how he moved his paralyzed legs. InAugust 2023 , the Company also completed the successful first-in-human use of an implanted BCI paired with the ARC-IM System to help a person with SCI recover thought-driven movement in his arms and hands. The Company calls this combined platform that enables thought-driven movement the “ARC-BCI™ System.” - Also in
May 2023 , the Company completed the successful first-in-human use of the ARC-IM Lead, designed to deliver ARC Therapy to areas of the spinal cord responsible for a specific function, such as mobility or blood pressure regulation. The Company is developing a portfolio of ARC-IM Leads, each optimized for placement on a different area of the spinal cord. - In
September 2023 , the Company expanded its HemON clinical feasibility study to explore use of the ARC-IM System to improve blood pressure regulation after SCI with the addition of Sint Maartenskliniek inthe Netherlands . This additional research site prepares the Company for expected Q4 2024 initiation of a global pivotal trial called Empower BP to assess the safety and efficacy of ARC-IM Therapy to improve blood pressure regulation. - In
November 2023 , the Company announced a publication in Nature Medicine highlighting the potential for ARC-IM Therapy to address gait challenges related to Parkinson’s disease. Also in November,ONWARD Medical research partner .NeuroRestore was awarded a$1 million grant fromThe Michael J. Fox Foundation for Parkinson’s Research (MJFF) to implant the Company’s ARC-IM System and investigate the impact of ARC-IM Therapy in six additional participants with Parkinson’s disease. - In 2023, the Company was awarded five new Breakthrough Device Designations (BDDs) by the
US Food & Drug Administration (FDA) for its ARC Therapy platforms, bringing the Company’s total number of BDDs to 9. A 10th BDD was added for ARC-BCI inFebruary 2024 . - In
March 2024 , ONWARD was only the second BCI company admitted into the FDA’s new Total Product Lifecycle Advisory Program (TAP) for its brain-computer interface technology. - In
April 2024 , the Company announced it had submitted a De Novo application to theUS FDA to obtain regulatory clearance to begin marketing its non-invasive ARC-EX System inthe United States . Clearance is expected Q4 2024.
Intellectual Property:
- The Company was issued more than 50 new patents during 2023, bringing its total number of issued patents to more than 240, further strengthening its first-mover advantage.
Commercial:
- In September, the Company announced a partnership with Lovell Government Services (Lovell), a Service-Disabled Veteran-Owned Small Business (SDVOSB). Lovell is a government vendor and third-party logistics provider partnering with more than one hundred US healthcare providers. The two-year distribution agreement gives the Company contract access to the
United States Veterans Health Administration , the world’s largest healthcare system providing SCI care, and theUS Department of Defense Military Health System , the world’s largest military healthcare provider.
Corporate:
- In Q1, the Company strengthened its leadership team, appointing
Erika Ross Ellison as Vice President, Global Clinical, Regulatory, and Quality, andSarah Moore as Vice President, Global Marketing. - In Q2,
Bryan, Garnier & Co reinitiated research coverage ofONWARD Medical following the appointment of a new equity research analyst. In 2024,KBC Securities and Stifel both initiated research coverage of the Company. Equity research analysts from 5 investment banks now cover ONWARD, each with a Buy rating and target price at a substantial premium to the current share price. - In Q3,
Robert Odell joined the Company as Vice President of Operations. Robert was formerly President and Chief Operating Officer ofCardiac Insight, Inc. Prior to that, he served as COO ofCardiac Science Corporation , a publicly traded manufacturer of Class II and Class III medical devices.
Financial:
- The Company ended the year with net cash of
EUR 29.8M (2022:EUR 61.8M ). - Management confirmed that with the gross proceeds of
EUR 20.0M from the share capital increase inMarch 2024 , the Company has a cash runway through mid-2025. - For 2023, the Company reported an operating loss of
EUR 35.5M compared toEUR 32.0M in 2022.
In EUR millions For the twelve-month period ended | 2023 | 2022 | ||
Total Revenues & Other Income | 0.5 | 2.1 | ||
Total Operating Expenses | (36.0 | ) | (34.2 | ) |
Operating Loss for the Period | (35.5 | ) | (32.0 | ) |
Net Finance Expenses | (0.6 | ) | (1.5 | ) |
Income Tax Expenses | (0.1 | ) | 0.8 | |
Net Loss for the Period | (36.2 | ) | (32.8 | ) |
At | ||||
Cash position at the end of the period | 29.8 | 61.8 | ||
Interest Bearing Loans | (15.3 | ) | (12.7 | ) |
Equity | 17.9 | 52.6 |
Total Revenues & Other Income
- Other Income, mainly grant income, decreased to
EUR 0.5M (2022:EUR 2.1M ) mainly due to a change in recognition of grant income.
Total Operating Expenses
- Total Operating expenses increased during 2023 by
EUR 1.8M toEUR 36.0M (2022:EUR 34.2M ). Research & Development (including Clinical) expenses were stable atEUR 18.8M (2022:EUR 18.9M ), mainly including costs to finalize all components of the ARC-EX platform for FDA submission. Marketing expenses increased fromEUR 2.0M in 2022 toEUR 2.9M driven by heightened market access activities in preparation for ARC-EX launch, including pricing studies and congress attendance to build awareness for the Company’s therapies within theSCI Community . General and Administrative expenses increased by 7% up toEUR 11.3M in 2023 (2022:EUR 10.6M ) mainly due to the strengthening of overall operational capabilities to prepare the launch of the Company’s first commercial product.
Net Finance Expenses
- Net Finance expense decreased from
EUR 1.5M in 2022 toEUR 0.6M in 2023 due to higher financial income related to interest earned from our positive cash balance in fixed term deposits. The financial expense is related to the interest expense on the Company’s longstanding innovation loan from theNetherland Enterprise Agency (RVO).
Net Loss for the Period
- The Company realized a Net Loss for the period of
EUR 36.2M versusEUR 32.8M in 2022 driven by the lower grant income and higher operating expenses.
Net Cash Position
- The Company ended the year 2023 with a net cash position of
EUR 29.8M (2022:EUR 61.8M ). Cash outflow from operating activities increased fromEUR 26.7M in 2022 toEUR 32.3M in 2023 driven by the higher operating loss and changes in working capital. Cash flow from financing activities wasEUR 0.8M positive (2022:EUR 0.6M negative) driven by proceeds from the RVO loan.
2024 Outlook
Innovation, Clinical and Regulatory Developments:
- On
April 2 nd, the Company announced it submitted a De Novo application for FDA clearance for the ARC-EX System, with an anticipated authorization to commercialize the platform in the US in the second half of 2024. The Company aims to apply for CE Mark and European authorization in 2025. - Based on positive feedback from potential customers on the value of the ARC-EX System, now demonstrated to be the first-ever therapy to restore hand and arm function after chronic SCI, the Company anticipates an approximate list price of
USD 30,000 . In addition, the Company expects to supplement revenue by offering tiered service packages. - The Company plans to apply for FDA IDE approval and to begin its global pivotal trial for the ARC-IM System, called Empower BP, in the second half of 2024 to provide the evidence necessary to ultimately submit a pre-market approval (PMA) application to the
US Food and Drug Administration (FDA) and other global regulatory bodies. - The Company intends to gain additional clinical data and experience with its implantable ARC-IM System in 2024, with several implants planned with support from the
Michael J. Fox Foundation for Parkinson’s Research and several ARC-IM System implants planned in combination with an implanted brain-computer interface (BCI) with support from theEuropean Innovation Council . The Company calls this BCI-augmented system, ARC-BCI.
Corporate:
- At year-end 2023, the Company anticipated its cash position would fuel operations through the end of 2024. In
March 2024 , the Company completed aEUR 20M equity financing that strengthened its cash position to support investments in product development, clinical trials, operational and commercial capabilities, and extending its cash runway through mid-2025.
To learn more about ONWARD Medical’s commitment to partnering with the
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
About ONWARD Medical
ONWARD® Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical, and clinical research conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy™, which has been awarded ten Breakthrough Device Designations from the
ONWARD ARC Therapy, which can be delivered by external ARC-EX® or implantable ARC-IM® systems, is designed to deliver targeted, programmed spinal cord stimulation. Positive results were presented in 2023 from the Company’s pivotal study, called Up-LIFT, evaluating the ability for transcutaneous ARC Therapy to improve upper extremity strength and function. The Company has submitted its regulatory application to the FDA for clearance of the ARC-EX System in the US and is preparing for regulatory submission in
Headquartered in Eindhoven,
For more information, visit ONWD.com, and connect with us on LinkedIn and YouTube.
For Media Inquiries:
media@onwd.com
For Investor Inquiries:
investors@onwd.com
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All
_______________________________________
1 Responder defined as a participant who met or exceeded the minimally important difference (MID) criteria for at least one outcome of the strength domain and at least one outcome of the functional performance domain. Responders had an average time since injury of 6 years, with a range of 1-34 years.
Source:
2024 GlobeNewswire, Inc., source